Dina Medina-Vera

Mrs. Dina Medina-Vera

Instituto de investigación Biomédica de Málaga-IBIMA, Universidad de Málaga, Hospital Regional Universitario de Málaga, Málaga, Spain
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
MSMARIA JOSE SANCHEZ-QUINTERO
MARIA JOSE SANCHEZ-QUINTERO
Josué DelgadoJosué Delgado
Josué Delgado
Dina Medina-VeraDina Medina-Vera
Dina Medina-Vera
VBVictor M. Becerra-Munoz
Victor M. Becerra-Munoz
MQMaría Isabel Queipo-Ortuño
María Isabel Queipo-Ortuño
Francisco Javier Pavón MorónFrancisco Javier Pavón Morón
Francisco Javier Pavón Morón
Ischemic heart disease (IHD) and type-2 diabetes mellitus (T2DM) remain major health problems worldwide and commonly coexist in individuals. Gut microbial metabolites, such as trimethylamine N-oxide (TMAO) and short-chain fatty acids (SCFAs), have been linked to cardiovascular and metabolic diseases. Previous studies have reported dysbiosis in the gut microbiota of these patients and the prebiotic effects of some components of the Mediterranean diet. Essential oil emulsions of savory (Satureja hortensis), parsley (Petroselinum crispum) and rosemary (Rosmarinus officinalis) were assessed as nutraceuticals and prebiotics in IHD and T2DM. Humanized mice harboring gut microbiota derived from that of patients with IHD and T2DM were supplemented with L-carnitine and orally treated with essential oil emulsions for 40 days. We assessed the effects on gut microbiota composition and abundance, microbial metabolites and plasma markers of cardiovascular disease, inflammation and oxidative stress. Our results showed that essential oil emulsions in mice supplemented with L-carnitine have prebiotic effects on beneficial commensal bacteria, mainly Lactobacillus genus. There was a decrease in plasma TMAO and an increase in fecal SCFAs levels in mice treated with parsley and rosemary essential oils. Thrombomodulin levels were increased in mice treated with savory and parsley essential oils. While mice treated with parsley and rosemary essential oils showed a decrease in plasma cytokines (INFɣ, TNFα, IL-12p70 and IL-22); savory essential oil was associated with increased levels of chemokines (CXCL1, CCL2 and CCL11). Finally, there was a decrease in protein carbonyls and pentosidine according to the essential oil emulsion. These results suggest that changes in the gut microbiota induced by essential oils of parsley, savory and rosemary as prebiotics could differentially regulate cardiovascular and metabolic factors, which highlights the potential of these nutraceuticals for reducing IHD risk in patients affected by T2DM.

Verified
Journal Article
Open access
PDF file
Antonio Jesús López-GamberoAntonio Jesús López-Gambero
Antonio Jesús López-Gambero
CVCristina Rosell del Valle
Cristina Rosell del Valle
Dina Medina-VeraDina Medina-Vera
Dina Medina-Vera
JGJuan Antonio Navarro Galera
Juan Antonio Navarro Galera
AVAntonio Vargas
Antonio Vargas
Juan SuárezJuan Suárez
Juan Suárez
Increasing evidence links metabolic disorders with neurodegenerative processes including Alzheimer’s disease (AD). Late AD is associated with amyloid (Aβ) plaque accumulation, neuroinflammation, and central insulin resistance. Here, a humanized AD model, the 5xFAD mouse model, was used to further explore food intake, energy expenditure, neuroinflammation, and neuroendocrine signaling in the hypothalamus. Experiments were performed on 6-month-old male and female full transgenic (Tg5xFAD/5xFAD), heterozygous (Tg5xFAD/-), and non-transgenic (Non-Tg) littermates. Although histological analysis showed absence of Aβ plaques in the hypothalamus of 5xFAD mice, this brain region displayed increased protein levels of GFAP and IBA1 in both Tg5xFAD/- and Tg5xFAD/5xFAD mice and increased expression of IL-1β in Tg5xFAD/5xFAD mice, suggesting neuroinflammation. This condition was accompanied by decreased body weight, food intake, and energy expenditure in both Tg5xFAD/- and Tg5xFAD/5xFAD mice. Negative energy balance was associated with altered circulating levels of insulin, GLP-1, GIP, ghrelin, and resistin; decreased insulin and leptin hypothalamic signaling; dysregulation in main metabolic sensors (phosphorylated IRS1, STAT5, AMPK, mTOR, ERK2); and neuropeptides controlling energy balance (NPY, AgRP, orexin, MCH). These results suggest that glial activation and metabolic dysfunctions in the hypothalamus of a mouse model of AD likely result in negative energy balance, which may contribute to AD pathogenesis development.

11 February 2020 in Addiction Biology
Verified
Journal Article
Closed access
PDF file
JLJuan Carlos Ledesma
Juan Carlos Ledesma
MRMarta Rodríguez‐Arias
Marta Rodríguez‐Arias
AGAna L. Gavito
Ana L. Gavito
Ana María Sánchez-PérezAna María Sánchez-Pérez
Ana María Sánchez-Pérez
JVJosé Viña
José Viña
JMJosé Miñarro
José Miñarro

5 November 2020 in Biology
Verified
Journal Article
Open access
PDF file
Dina Medina-VeraDina Medina-Vera
Dina Medina-Vera
CVCristina Rosell del Valle
Cristina Rosell del Valle
Antonio Jesús López-GamberoAntonio Jesús López-Gambero
Antonio Jesús López-Gambero
JGJuan Antonio Navarro Galera
Juan Antonio Navarro Galera
EZEmma N. Zambrana-Infantes
Emma N. Zambrana-Infantes
FFFERNANDO DE FONSECA
FERNANDO DE FONSECA
Alzheimer’s disease (AD) is the most common form of neurodegeneration and dementia. The endocannabinoid (ECB) system has been proposed as a novel therapeutic target to treat AD. The present study explores the expression of the ECB system, the ECB-related receptor GPR55, and cognitive functions (novel object recognition; NOR) in the 5xFAD (FAD: family Alzheimer’s disease) transgenic mouse model of AD. Experiments were performed on heterozygous (HTZ) and homozygous (HZ) 11 month old mice. Protein expression of ECB system components, neuroinflammation markers, and β-amyloid (Aβ) plaques were analyzed in the hippocampus. According to the NOR test, anxiety-like behavior and memory were altered in both HTZ and HZ 5xFAD mice. Furthermore, both animal groups displayed a reduction of cannabinoid (CB1) receptor expression in the hippocampus, which is related to memory dysfunction. This finding was associated with indirect markers of enhanced ECB production, resulting from the combination of impaired monoacylglycerol lipase (MAGL) degradation and increased diacylglycerol lipase (DAGL) levels, an effect observed in the HZ group. Regarding neuroinflammation, we observed increased levels of CB2 receptors in the HZ group that positively correlate with Aβ’s accumulation. Moreover, HZ 5xFAD mice also exhibited increased expression of the GPR55 receptor. These results highlight the importance of the ECB signaling for the AD pathogenesis development beyond Aβ deposition.

8 July 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
JGJuan Antonio Navarro Galera
Juan Antonio Navarro Galera
JDJuan Decara
Juan Decara
Dina Medina-VeraDina Medina-Vera
Dina Medina-Vera
RTRubén Tovar
Rubén Tovar
Juan SuárezJuan Suárez
Juan Suárez
FFFERNANDO DE FONSECA
FERNANDO DE FONSECA
To characterize the metabolic actions of D-Pinitol, a dietary inositol, in male Wistar rats, we analyzed its oral pharmacokinetics and its effects on (a) the secretion of hormones regulating metabolism (insulin, glucagon, IGF-1, ghrelin, leptin and adiponectin), (b) insulin signaling in the liver and (c) the expression of glycolytic and neoglucogenesis enzymes. Oral D-Pinitol administration (100 or 500 mg/Kg) resulted in its rapid absorption and distribution to plasma and liver compartments. Its administration reduced insulinemia and HOMA-IR, while maintaining glycaemia thanks to increased glucagon activity. In the liver, D-Pinitol reduced the key glycolytic enzyme pyruvate kinase and decreased the phosphorylation of the enzymes AKT and GSK-3. These observations were associated with an increase in ghrelin concentrations, a known inhibitor of insulin secretion. The profile of D-Pinitol suggests its potential use as a pancreatic protector decreasing insulin secretion through ghrelin upregulation, while sustaining glycaemia through the liver-based mechanisms of glycolysis control.

31 May 2023 in Biology
Verified
Journal Article
Open access
PDF file
Dina Medina-VeraDina Medina-Vera
Dina Medina-Vera
HZHongjing Zhao
Hongjing Zhao
Erika BereczkiErika Bereczki
Erika Bereczki
CVCristina Rosell del Valle
Cristina Rosell del Valle
MSMakoto Shimozawa
Makoto Shimozawa
Simone TambaroSimone Tambaro
Simone Tambaro
Background: The endocannabinoid system (ECS) and associated lipid transmitter-based signaling systems play an important role in modulating brain neuroinflammation. ECS is affected in neurodegenerative disorders, such as Alzheimer’s disease (AD). Here we have evaluated the non-psychotropic endocannabinoid receptor type 2 (CB2) and lysophosphatidylinositol G-protein-coupled receptor 55 (GPR55) localization and expression during Aβ-pathology progression. Methods: Hippocampal gene expression of CB2 and GPR55 was explored by qPCR analysis, and brain distribution was evaluated by immunofluorescence in the wild type (WT) and APP knock-in AppNL-G-F AD mouse model. Furthermore, the effects of Aβ42 on CB2 and GPR55 expression were assessed in primary cell cultures. Results: CB2 and GPR55 mRNA levels were significantly upregulated in AppNL-G-F mice at 6 and 12 months of age, compared to WT. CB2 was highly expressed in the microglia and astrocytes surrounding the Aβ plaques. Differently, GPR55 staining was mainly detected in neurons and microglia but not in astrocytes. In vitro, Aβ42 treatment enhanced CB2 receptor expression mainly in astrocytes and microglia cells, whereas GPR55 expression was enhanced primarily in neurons. Conclusions: These data show that Aβ pathology progression, particularly Aβ42, plays a crucial role in increasing the expression of CB2 and GPR55 receptors, supporting CB2 and GPR55 implications in AD.